| scholarly article | Q13442814 |
| P2093 | author name string | Jae H Park | |
| Renier J Brentjens | |||
| P2860 | cites work | Natural selection of tumor variants in the generation of "tumor escape" phenotypes | Q24551158 |
| Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen | Q24623215 | ||
| Cancer regression in patients after transfer of genetically engineered lymphocytes | Q24654976 | ||
| Antibody-mediated B-cell depletion before adoptive immunotherapy with T cells expressing CD20-specific chimeric T-cell receptors facilitates eradication of leukemia in immunocompetent mice | Q33560416 | ||
| Administration of cyclophosphamide changes the immune profile of tumor-bearing mice | Q33611809 | ||
| Adult acute lymphocytic leukemia study testing chemotherapy and autologous and allogeneic transplantation. A follow-up report of the French protocol LALA 87. | Q34123864 | ||
| Sinks, suppressors and antigen presenters: how lymphodepletion enhances T cell-mediated tumor immunotherapy. | Q34422330 | ||
| Myeloablative allografting for chronic lymphocytic leukemia: evidence for a potent graft-versus-leukemia effect associated with graft-versus-host disease | Q34449575 | ||
| Development and application of CD19-specific T cells for adoptive immunotherapy of B cell malignancies | Q35820481 | ||
| Autologous and allogeneic stem cell transplantations for poor-risk chronic lymphocytic leukemia | Q35848136 | ||
| T lymphocytes redirected against the kappa light chain of human immunoglobulin efficiently kill mature B lymphocyte-derived malignant cells | Q35848840 | ||
| Eight-year experience with allogeneic stem cell transplantation for relapsed follicular lymphoma after nonmyeloablative conditioning with fludarabine, cyclophosphamide, and rituximab | Q36219690 | ||
| The role of cytotoxic therapy with hematopoietic stem cell transplantation in the therapy of acute lymphoblastic leukemia in adults: an evidence-based review. | Q36363377 | ||
| Human T-cell clonal anergy is induced by antigen presentation in the absence of B7 costimulation | Q36420205 | ||
| Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells | Q36868712 | ||
| Antigen sensitivity of CD22-specific chimeric TCR is modulated by target epitope distance from the cell membrane. | Q36979111 | ||
| Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domains. | Q37117781 | ||
| Qualitative and quantitative polymerase chain reaction monitoring of minimal residual disease in relapsed chronic lymphocytic leukemia: early assessment can predict long-term outcome after reduced intensity allogeneic transplantation | Q37175581 | ||
| Clinical evidence of a graft-versus-lymphoma effect against relapsed diffuse large B-cell lymphoma after allogeneic hematopoietic stem-cell transplantation | Q37321812 | ||
| Construction and preclinical evaluation of an anti-CD19 chimeric antigen receptor | Q37354362 | ||
| Adoptive T cell immunotherapy strategies for the treatment of patients with ovarian cancer. | Q37681678 | ||
| Natural expression of the CD19 antigen impacts the long-term engraftment but not antitumor activity of CD19-specific engineered T cells. | Q39749811 | ||
| Immunotherapy of lymphomas with T cells modified by anti-CD20 scFv/CD28/CD3zeta recombinant gene | Q39986134 | ||
| Cyclophosphamide enhances the antitumor efficacy of adoptively transferred immune cells through the induction of cytokine expression, B-cell and T-cell homeostatic proliferation, and specific tumor infiltration | Q40178764 | ||
| Elimination of human leukemia cells in NOD/SCID mice by WT1-TCR gene-transduced human T cells | Q40397520 | ||
| A chimeric T cell antigen receptor that augments cytokine release and supports clonal expansion of primary human T cells | Q40404804 | ||
| Killing of non-Hodgkin lymphoma cells by autologous CD19 engineered T cells | Q40432901 | ||
| Cellular immunotherapy for follicular lymphoma using genetically modified CD20-specific CD8+ cytotoxic T lymphocytes | Q40565585 | ||
| Chimeric receptors with 4-1BB signaling capacity provoke potent cytotoxicity against acute lymphoblastic leukemia. | Q40590332 | ||
| Activation of resting human primary T cells with chimeric receptors: costimulation from CD28, inducible costimulator, CD134, and CD137 in series with signals from the TCR zeta chain | Q40605275 | ||
| An Epstein-Barr virus deletion mutant associated with fatal lymphoproliferative disease unresponsive to therapy with virus-specific CTLs | Q40830952 | ||
| CD20 is a molecular target for scFvFc:zeta receptor redirected T cells: implications for cellular immunotherapy of CD20+ malignancy | Q41004760 | ||
| Cellular therapies in acute lymphoblastic leukemia. | Q41560177 | ||
| Adoptive immunotherapy of disseminated leukemia with TCR-transduced, CD8+ T cells expressing a known endogenous TCR. | Q42176846 | ||
| Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivo | Q42938990 | ||
| T cell proliferation induced by autologous non-T cells is a response to apoptotic cells processed by dendritic cells | Q44074285 | ||
| The toxicity and efficacy of donor lymphocyte infusions given after reduced-intensity conditioning allogeneic stem cell transplantation | Q44182914 | ||
| Graft-versus-lymphoma effect of donor lymphocyte infusion in indolent lymphomas relapsed after allogeneic stem cell transplantation | Q44675138 | ||
| Addition of the CD28 signaling domain to chimeric T-cell receptors enhances chimeric T-cell resistance to T regulatory cells | Q45862006 | ||
| CD28 costimulation provided through a CD19-specific chimeric antigen receptor enhances in vivo persistence and antitumor efficacy of adoptively transferred T cells. | Q45984095 | ||
| Engineered CD20-specific primary human cytotoxic T lymphocytes for targeting B-cell malignancy | Q47563589 | ||
| T-cell clones can be rendered specific for CD19: toward the selective augmentation of the graft-versus-B-lineage leukemia effect | Q47567565 | ||
| The combination of cyclophosphamide and human T cells genetically engineered to target CD19 can eradicate established B-cell lymphoma | Q47710513 | ||
| Genetically targeted T cells eradicate systemic acute lymphoblastic leukemia xenografts | Q50085632 | ||
| Eradication of established B-cell lymphoma by CD19-specific murine T cells is dependent on host lymphopenic environment and can be mediated by CD4+ and CD8+ T cells. | Q51800063 | ||
| Eradication of systemic B-cell tumors by genetically targeted human T lymphocytes co-stimulated by CD80 and interleukin-15. | Q53659254 | ||
| Allogeneic hematopoietic stem cell transplantation as part of postremission therapy improves survival for adult patients with high-risk acute lymphoblastic leukemia | Q57918815 | ||
| Inhibition of antigen-specific proliferation of type 1 murine T cell clones after stimulation with immobilized anti-CD3 monoclonal antibody | Q68447043 | ||
| Outcome of treatment in adults with acute lymphoblastic leukemia: analysis of the LALA-94 trial | Q80537988 | ||
| Optimizing adoptive polyclonal T cell immunotherapy of lymphomas, using a chimeric T cell receptor possessing CD28 and CD137 costimulatory domains | Q80765390 | ||
| Quantitative MRD monitoring identifies distinct GVL response patterns after allogeneic stem cell transplantation for chronic lymphocytic leukemia: results from the GCLLSG CLL3X trial | Q81100907 | ||
| Allogeneic hematopoietic stem-cell transplantation for chronic lymphocytic leukemia with 17p deletion: a retrospective European Group for Blood and Marrow Transplantation analysis | Q81798456 | ||
| Tumor-specific T cell activation by recombinant immunoreceptors: CD3 zeta signaling and CD28 costimulation are simultaneously required for efficient IL-2 secretion and can be integrated into one combined CD28/CD3 zeta signaling receptor molecule | Q94028937 | ||
| P433 | issue | 47 | |
| P921 | main subject | immunotherapy | Q1427096 |
| P304 | page(s) | 277-288 | |
| P577 | publication date | 2010-04-01 | |
| P1433 | published in | Discovery Medicine | Q5281940 |
| P1476 | title | Adoptive immunotherapy for B-cell malignancies with autologous chimeric antigen receptor modified tumor targeted T cells | |
| P478 | volume | 9 |
| Q39381573 | A caspase 8-based suicide switch induces apoptosis in nanobody-directed chimeric receptor expressing T cells |
| Q92864734 | At the Intersection of Biomaterials and Gene Therapy: Progress in Non-viral Delivery of Nucleic Acids |
| Q90212066 | Bispecific T-Cell Redirection versus Chimeric Antigen Receptor (CAR)-T Cells as Approaches to Kill Cancer Cells |
| Q37058098 | CD19-targeted CAR T-cell therapeutics for hematologic malignancies: interpreting clinical outcomes to date |
| Q36552098 | Cellular therapies in acute lymphoblastic leukemia |
| Q89562804 | Chimeric Antigen Receptor T Cell Therapy for Acute Lymphoblastic Leukemia |
| Q42654456 | Clinical trials of CAR-T cells in China |
| Q40077818 | Current progress in innovative engineered antibodies |
| Q58556647 | Frontiers and Opportunities: Highlights of the 2 Annual Conference of the Chinese Antibody Society |
| Q41660817 | Human CD3+ T-Cells with the Anti-ERBB2 Chimeric Antigen Receptor Exhibit Efficient Targeting and Induce Apoptosis in ERBB2 Overexpressing Breast Cancer Cells |
| Q92811129 | Immunosurveillance and Immunoediting of Lung Cancer: Current Perspectives and Challenges |
| Q48669191 | International Working Group consensus response evaluation criteria in lymphoma (RECIL 2017). |
| Q38195539 | Novel antibody therapy in acute lymphoblastic leukemia |
| Q26751214 | Recent advances in the management of Hodgkin lymphoma |
| Q38945853 | Review: Current clinical applications of chimeric antigen receptor (CAR) modified T cells |
| Q29622949 | Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias |
| Q38267385 | The inducible caspase-9 suicide gene system as a "safety switch" to limit on-target, off-tumor toxicities of chimeric antigen receptor T cells. |
| Q36110355 | Tolerance and efficacy of autologous or donor-derived T cells expressing CD19 chimeric antigen receptors in adult B-ALL with extramedullary leukemia |
| Q59326961 | Universal CARs, universal T cells, and universal CAR T cells |
| Q52650265 | [Anti-CD19 chimeric antigen receptors T cells for treatment of relapsed or refractory E2A-PBX1 positive acute lymphoblastic leukemia: three cases report and literatures review]. |
Search more.